FLNC Gene

FLNC Gene

Overview

FLNC (Filamin C), also known as Filamin C, is a large actin-binding protein that plays essential roles in maintaining the structural integrity of skeletal and cardiac muscle. As a member of the filamin family of proteins, FLNC functions as an actin-crosslinking protein that organizes actin filaments into three-dimensional networks and connects these networks to cellular membranes and protein complexes. The protein is particularly enriched at the Z-disc and myotendinous junctions of muscle fibers, where it serves as a critical link between the contractile apparatus and the extracellular matrix.

FLNC Gene

Overview

FLNC (Filamin C), also known as Filamin C, is a large actin-binding protein that plays essential roles in maintaining the structural integrity of skeletal and cardiac muscle. As a member of the filamin family of proteins, FLNC functions as an actin-crosslinking protein that organizes actin filaments into three-dimensional networks and connects these networks to cellular membranes and protein complexes. The protein is particularly enriched at the Z-disc and myotendinous junctions of muscle fibers, where it serves as a critical link between the contractile apparatus and the extracellular matrix.

Mutations in the FLNC gene cause a spectrum of muscle disorders, ranging from isolated cardiomyopathy to combined skeletal and cardiac myopathies. The identification of FLNC mutations in patients with amyotrophic lateral sclerosis (ALS) has expanded the understanding of this gene's role in the nervous system. The protein's functions in mechanotransduction, protein quality control, and cellular signaling make it a critical player in muscle biology and disease.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.2em;">FLNC</th></tr>
<tr><td colspan="2" style="text-align:center;font-style:italic;">Filamin C</td></tr>
<tr><th style="width:40%;">Gene Symbol</th><td><strong>FLNC</strong></td></tr>
<tr><th>Full Name</th><td>Filamin C</td></tr>
<tr><th>Chromosome</th><td>7q32.1</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/2318" target="_blank">2318</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128591" target="_blank">ENSG00000128591</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/612121" target="_blank">612121</a></td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q14315" target="_blank">Q14315</a></td></tr>
<tr><th>Protein Length</th><td>2,632 amino acids</td></tr>
<tr><th>Molecular Weight</th><td>291 kDa</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/myofibrillar-myopathy" style="color:#ef9a9a">Myofibrillar Myopathy</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">22 edges</a></td>
</tr>
</table>
</div>

Gene Structure and Expression

Genomic Organization

The FLNC gene is located on chromosome 7q32.1 and spans approximately 30 kilobases. The gene consists of 48 exons that encode a massive 2,632-amino acid protein. The large size of FLNC reflects its modular architecture, with multiple repeat domains that mediate protein-protein interactions. This genomic organization is notable because many disease-causing mutations cluster in specific regions of the gene that encode functionally important protein domains.

The promoter region of FLNC contains regulatory elements that direct muscle-specific expression. The gene is primarily expressed in skeletal and cardiac muscle, with lower levels detected in some other tissues. Transcriptional regulation involves multiple muscle-specific transcription factors, and alternative splicing generates tissue-specific isoforms.

Tissue Distribution

FLNC exhibits a muscle-specific expression pattern:

• Skeletal Muscle: Very high expression in all major skeletal muscle groups, concentrated at the Z-disc and myotendinous junctions.
• Cardiac Muscle: High expression in both ventricular and atrial myocardium, particularly in the left ventricle.
• Smooth Muscle: Low expression in some smooth muscle populations.
• Non-muscle Tissues: Minimal expression outside of muscle tissues, confirming its role as a muscle-specific protein.

Protein Structure and Function

Domain Architecture

FLNC is a large, modular protein with multiple functional domains:

Normal Cellular Functions

FLNC performs several essential functions in muscle cells:

Actin Crosslinking

The primary function of FLNC is to crosslink actin filaments:

• Z-Disc Organization: FLNC crosslinks actin filaments at the Z-disc, maintaining the structural integrity of the sarcomere.
• Membrane Connections: FLNC connects actin filaments to the sarcolemma at the myotendinous junction.
• Cytoplasmic Connections: The protein links the contractile apparatus to the subsarcolemmal cytoskeleton.
• Force Transmission: By connecting multiple actin networks, FLNC contributes to lateral force transmission within muscle fibers.

Protein Scaffold

FLNC serves as a molecular scaffold that organizes protein complexes:

• Z-disc Protein Network: FLNC interacts with multiple Z-disc proteins including myotilin, alpha-actinin, and titin.
• Signaling Complexes: The protein recruits signaling molecules to specific cellular locations.
• Mechanosensation: FLNC participates in signaling pathways that respond to mechanical stress.

Mechanotransduction

FLNC is involved in converting mechanical signals into biochemical responses:

• Force Sensing: The protein senses mechanical force and transmits this information to signaling pathways.
• Adaptive Responses: Mechanical loading induces changes in FLNC phosphorylation and localization.
• Structural Remodeling: FLNC participates in muscle remodeling in response to exercise or injury.

Protein Quality Control

FLNC participates in cellular protein quality control:

• Aggregate Formation: Under stress conditions, FLNC can form aggregates called agrisomes.
• Autophagy: FLNC aggregates are cleared through autophagy pathways.
• Degradation Pathways: The protein is degraded through both proteasomal and lysosomal pathways.

Disease Associations

Myofibrillar Myopathy (MFM)

FLNC mutations are a well-established cause of myofibrillar myopathy [@gontier2019]:

Pathogenesis

• Protein Aggregation: Mutant FLNC proteins form abnormal aggregates within muscle fibers.
• Z-Disc Disruption: The normal Z-disc architecture is disrupted by FLNC-positive inclusions.
• Sarcomere Dysfunction: Abnormalities in force generation and transmission result from FLNC dysfunction.
• Protein Quality Control Failure: Impaired degradation leads to accumulation of damaged proteins.

Clinical Features

• Adult Onset: Most patients present in adulthood with progressive muscle weakness.
• Distal Predominance: Weakness often begins in distal muscles and progresses proximally.
• Cardiac Involvement: Many patients develop cardiomyopathy, sometimes preceding skeletal symptoms.
• Respiratory Dysfunction: Respiratory muscle involvement may develop in advanced disease.
• Areflexia: Deep tendon reflexes may be diminished or absent.

Pathological Features

• Rimmed Vacuoles: Muscle biopsies show characteristic rimmed vacuoles.
• Protein Aggregates: Immunohistochemistry demonstrates FLNC-positive inclusions.
• Z-Disc Streaming: Disruption of normal Z-disc architecture.
• Fiber Type Variation: Variable fiber size and type grouping.

Dilated Cardiomyopathy (DCM)

FLNC mutations cause isolated cardiomyopathy [@duff2019]:

Clinical Presentation

• Systolic Dysfunction: Reduced left ventricular ejection fraction.
• Ventricular Dilation: Dilated left ventricle with spherical remodeling.
• Arrhythmias: Atrial and ventricular arrhythmias may occur.
• Heart Failure: Progressive heart failure symptoms develop over time.

Treatment Response

• Medical Therapy: Standard heart failure therapies are effective.
• Device Therapy: Many patients require ICD or CRT devices.
• Transplantation: Some patients progress to requiring cardiac transplantation.

Arrhythmogenic Cardiomyopathy

FLNC mutations have been implicated in arrhythmogenic cardiomyopathy [@lozano2021]:

• Ventricular Arrhythmias: Increased risk of ventricular tachycardia.
• Fibrofatty Replacement: Histological changes in the ventricular myocardium.
• Sudden Cardiac Death: Risk of sudden cardiac death, particularly in younger patients.

Amyotrophic Lateral Sclerosis (ALS)

The identification of FLNC mutations in ALS patients represents a significant finding [@wang2020]:

Genetic Evidence

• Rare Variants: Rare missense variants in FLNC have been identified in ALS patients.
• Segregation: Some variants show segregation within families.
• Frequency: FLNC variants account for a small percentage of ALS cases.

Potential Mechanisms

• Motor Neuron Dysfunction: FLNC may be important for motor neuron viability.
• Muscle Involvement: Some FLNC-related ALS cases show combined upper and lower motor neuron features.
• Sporadic and Familial: Variants identified in both sporadic and familial ALS.

Rippling Muscle Disease

FLNC mutations have been associated with rippling muscle disease:

• Muscle Rigidity: Patients exhibit muscle stiffness and rippling.
• Myotonia-Like Phenotype: Electrical myotonia without myotonic discharges.
• Autosomal Dominant Inheritance: Usually inherited in an autosomal dominant pattern.

Pediatric Myopathies

FLNC mutations can cause early-onset myopathies:

• Congenital Myopathy: Some patients present at birth or in early infancy.
• Developmental Delay: Motor developmental delays may be present.
• Cardiac Involvement: Congenital or infantile cardiomyopathy may occur.

Molecular Mechanisms

Pathogenic Mechanisms

The mechanisms by which FLNC mutations cause disease include:

Loss of Function

• Truncated Proteins: Nonsense and frameshift mutations produce truncated proteins.
• Misfolded Proteins: Missense mutations may cause improper folding.
• Reduced Expression: Some mutations affect RNA stability, reducing protein levels.

Toxic Gain of Function

• Aggregate Formation: Mutant FLNC forms intracellular aggregates.
• Dominant-Negative Effects: Mutant proteins may interfere with normal FLNC function.
• Cellular Stress: Aggregates cause cellular stress and activate quality control pathways.

Disrupted Interactions

• Partner Protein Binding: Mutations may disrupt binding to FLNC interaction partners.
• Z-Disc Instability: Impaired interactions lead to Z-disc instability.
• Signaling Dysregulation: Altered signaling due to disrupted protein interactions.

Signaling Pathways

FLNC participates in multiple signaling pathways:

Mechanical Signaling

• Integrin Signaling: FLNC connects to integrins at the cell membrane.
• Focal Adhesion Kinase: Mechanical signals activate FAK signaling.
• MAPK Pathways: Mechanical stress activates MAPK cascades.

Protein Quality Control

• Ubiquitin-Proteasome System: Most FLNC degradation occurs through the proteasome.
• Autophagy-Lysosome Pathway: Aggregate clearance involves autophagy.
• ER Stress: Mutant FLNC may induce ER stress responses.

Animal Models

Knockout Mice

Mice lacking FLNC have been generated:

• Muscle Abnormalities: Significant structural and functional muscle abnormalities.
• Cardiac Phenotype: Cardiac dysfunction develops in knockout mice.
• Compensation: Other filamins may partially compensate for FLNC loss.

Transgenic Models

Transgenic mice expressing mutant FLNC develop myopathy:

• Aggregate Formation: FLNC-positive inclusions form in muscle fibers.
• Progressive Weakness: Animals develop age-related muscle weakness.
• Cardiac Involvement: Cardiac abnormalities develop in some models.

Clinical Diagnosis

Genetic Testing

Molecular diagnosis involves:

Clinical Evaluation

Patients require comprehensive assessment:

• Neurological Examination: Detailed strength assessment.
• Cardiac Evaluation: ECG, echocardiography, and sometimes cardiac MRI.
• Pulmonary Function Tests: Evaluation of respiratory muscle function.
• Family Screening: Cascade testing of at-risk family members.

Muscle Biopsy

When performed, muscle biopsy shows:

• Immunohistochemistry: FLNC-positive aggregates.
• Electron Microscopy: Z-disc abnormalities and aggregate structures.
• Standard Histology: Rimmed vacuoles, fiber type variation.

Treatment and Management

Current Therapies

No disease-specific treatments exist:

• Symptomatic Management: Physical therapy, occupational therapy.
• Cardiac Management: Standard heart failure and arrhythmia therapies.
• Respiratory Support: Non-invasive ventilation as needed.
• Assistive Devices: Mobility aids and adaptive equipment.

Experimental Approaches

Research is ongoing to develop novel treatments:

• Gene Therapy: Approaches to deliver functional FLNC.
• Aggregation Inhibitors: Small molecules that prevent aggregate formation.
• Quality Control Enhancement: Enhancing autophagy to clear aggregates.

Research Directions

Biomarker Development

• Serum Biomarkers: Circulating FLNC fragments or related proteins.
• Imaging Markers: MRI to quantify muscle involvement.
• Functional Measures: Quantitative strength testing.

Mechanism Studies

• Protein Interactions: Mapping FLNC interaction networks.
• Cellular Pathways: Understanding disease-specific pathways.
• Genotype-Phenotype: Correlating specific mutations with clinical presentation.

Genetics

Inheritance Patterns

FLNC-related diseases show autosomal dominant inheritance:

• De Novo Mutations: Many cases result from new mutations.
• Variable Expressivity: Different family members may have varying severity.
• Incomplete Penetrance: Some mutation carriers may not develop disease.

Known Variants

• Missense Mutations: Most common pathogenic variant type.
• Nonsense Mutations: Cause premature stop codons.
• Splice Site Mutations: Lead to exon skipping.
• Small Deletions/Insertions: Frameshift mutations.

Prognosis

The prognosis for FLNC-related disease varies:

• Disease Severity: Range from mild to severe.
• Cardiac Involvement: Major determinant of long-term prognosis.
• Age of Onset: Earlier onset often correlates with more severe disease.
• Progression Rate: Variable progression between patients.

Brain Atlas Resources

• Allen Human Brain Atlas: [Gene expression search](https://human.brain-map.org/microarray/search/show?search_term=FLNC)
• Allen Mouse Brain Atlas: [Gene search](https://mouse.brain-map.org/search/index.html?query=FLNC)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=FLNC)

References

See Also

• [Myofibrillar Myopathy](/diseases/myofibrillar-myopathy)
• [Dilated Cardiomyopathy](/diseases/dilated-cardiomyopathy)](/diseases/cardiomyopathy)
• [Arrhythmogenic Cardiomyopathy](/diseases/arrhythmogenic-cardiomyopathy)](/diseases/cardiomyopathy)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Myotilin](/genes/myot)](/genes)
• [Alpha-Actinin](/proteins/alpha-actinin)](/proteins)
• [Z-Disc](/entities/z-disc)](/entities)
• [Sarcomere](/entities/sarcomere)

External Links

• [NCBI Gene: FLNC](https://www.ncbi.nlm.nih.gov/gene/2318)
• [OMIM: 612121](https://www.omim.org/entry/612121)
• [UniProt: Q14315](https://www.uniprot.org/uniprot/Q14315)
• [Ensembl: ENSG00000128591](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128591)
• [HGNC: FLNC](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3752)

Pathway Diagram

The following diagram shows the key molecular relationships involving FLNC Gene discovered through SciDEX knowledge graph analysis: